Please login to the form below

Not currently logged in
Email:
Password:

Memorial Sloan Kettering

This page shows the latest Memorial Sloan Kettering news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Patients with unresectable liver cancer are in need of well-tolerated treatments that can meaningfully extend overall survival,” said Ghassan Abou-Alfa, attending physician at Memorial Sloan Kettering Cancer Center (MSK),

Latest news

More from news
Approximately 1 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Strategies for sourcing external innovation include collaborations with universities and leading academic research centers based on their research focus (eg, oncology companies partnering with Memorial Sloan Kettering Cancer Center) and geographic

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    He also cited an FDA-approved TMB test developed by Foundation Medicine and Memorial Sloan Kettering Cancer Center as an example.

  • Deal Watch September 2016 Deal Watch September 2016

    No other financial details were disclosed. Fate Therapeutics entered a three year arrangement with Memorial Sloan Kettering Cancer Center to use engineered pluripotent cell lines to develop T cell product candidates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ICR appoints Kristian Helin as its new chief executive ICR appoints Kristian Helin as its new chief executive

    Helin will join ICR in September from the Memorial Sloan Kettering Cancer Center in the US. ... Helin will join the ICR from Memorial Sloan Kettering Cancer Center in the US, where he currently serves as chair of the cell biology programme and director

  • Lilly appoints Maura Dickler as VP of late phase oncology development Lilly appoints Maura Dickler as VP of late phase oncology development

    She will join the pharma firm from the Memorial Sloan Kettering Cancer Center. ... She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and

  • OncoMed’s CMO steps down OncoMed’s CMO steps down

    Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Getting personal with wearable tech

    In July 2016, a prestigious US cancer centre, The Memorial Sloan Kettering Cancer Center (MSK), announced their plans to evaluate wearables and other mobile technology to assess cancer patients' quality of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...